July 9, 2016 09:13 AM EDTUpdated July 10, 02:21 PM
Bioregnum
Pharma
Opinion

Why we need to low­er U.S. reg­u­la­to­ry bar­ri­ers around biosim­i­lar ap­provals now

The FDA’s in­ter­nal re­view on Am­gen’s biosim­i­lar of Hu­mi­ra reads like a prod­uct en­dorse­ment. Post­ed on Fri­day, the agency in­sid­ers es­sen­tial­ly said: Let’s give it …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times